A multi-centre, multi-national, phase 3, randomized, double-blind, double-dummy, 3-arm parallel group, placebo- and pramipexole-controlled trial of the efficacy and safety of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa.

Trial Profile

A multi-centre, multi-national, phase 3, randomized, double-blind, double-dummy, 3-arm parallel group, placebo- and pramipexole-controlled trial of the efficacy and safety of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Pramipexole; Rotigotine
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms CLEOPATRA-PD
  • Sponsors UCB
  • Most Recent Events

    • 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results of post-hoc pooled analysis from patients who received levodopa doses in 8 randomized placebo-controlled studies, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 12 Feb 2016 Results of pooled post-hoc analysis of this and two other trials (see profile 26754 and 169511) published in the Clinical Neuropharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top